Graft-versus-host disease risk factors

Revision as of 17:54, 14 June 2017 by Shyam Patel (talk | contribs)
Jump to navigation Jump to search

Graft-versus-host disease

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Graft-versus-host disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Graft-versus-host disease risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Graft-versus-host disease risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Graft-versus-host disease risk factors

CDC on Graft-versus-host disease risk factors

Graft-versus-host disease risk factors in the news

Blogs on Graft-versus-host disease risk factors

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Graft-versus-host disease risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]

Overview

Risk Factors

Risk factors for GvHD include:

  • High degree of HLA disparity between host and donor cells[1]
  • Use of unrelated donors as the stem cell source[1]
  • Total body irradiation as the conditioning regimen prior to transplant[1]

Protective risk factors include:

  • High degree of HLA concordance between the host and donor
  • Use of umbilical cord blood as the donor source (given decreased number of donor T cells)

References

  1. 1.0 1.1 1.2 Rezvani AR, Storb RF (2012). "Prevention of graft-vs.-host disease". Expert Opin Pharmacother. 13 (12): 1737–50. doi:10.1517/14656566.2012.703652. PMC 3509175. PMID 22770714.

Template:WS Template:WH